EPICRISPR

Serial Number 98737774
688

Registration Progress

Application Filed
Sep 6, 2024
Under Examination
Jun 3, 2025
Approved for Publication
Apr 8, 2025
Published for Opposition
Apr 8, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Dec 03, 2025 146 days

Trademark Image

EPICRISPR

Basic Information

Serial Number
98737774
Deadline
December 3, 2025
Description
Statement of Use or 1st Extension Due
Filing Date
September 6, 2024
Published for Opposition
April 8, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Jun 3, 2025
Application
Pending
Classes
001 005 042 044

Rights Holder

Epicrispr Biotechnologies, Inc.

03
Address
7000 Shoreline Court, Ste 100
South San Francisco, CA 94080

Ownership History

Epicrispr Biotechnologies, Inc.

Original Applicant
03
South San Francisco, CA

Epicrispr Biotechnologies, Inc.

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
Salima A. Merani, Ph.D.

USPTO Deadlines

Next Deadline
146 days remaining
NOA E-Mailed - SOU Required
Due Date
December 03, 2025
Extension Available
Until June 03, 2026

Application History

8 events
Date Code Type Description
Jun 3, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 8, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 8, 2025 PUBO A PUBLISHED FOR OPPOSITION
Apr 2, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 12, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 10, 2025 DOCK D ASSIGNED TO EXAMINER
Jan 17, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 6, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 001
Assays and reagents for use in genetic research; Reagents for medical research; Reagents for research purposes; Reagents for scientific purposes
Class 005
Biological preparations for the treatment of gene expression; Biological reagents for medical use; Diagnostic preparations for medical purposes for detecting genetic predispositions; Pharmaceutical preparations for the treatment of muscular dystrophy, hypercholesterolemia, liver diseases, lung diseases, ophthalmic diseases, and cancer; Pharmaceutical preparations for controlling gene expression
Class 042
Pharmaceutical drug development services; Providing information about medical research in the field of gene expression and genetic modulators; Providing medical and scientific research information; Research and development in the pharmaceutical and biotechnology fields; Research in the field of genetic diseases
Class 044
Consultancy in the field of the medical treatment of genetic diseases; Genetic testing for medical purposes; Providing information about genetic testing for medical purposes; Providing medical information in the field of gene expression; Providing medical information via a website

Additional Information

Pseudo Mark
EPI CRISPR; EPIC CRISPER

Classification

International Classes
001 005 042 044